

Posting Date: November 23, 2022

Closing Date: December 3, 2022, 11:30 a.m. ET

Reference Number: 23-008406

To: NCI Bid Board

From: Viviane Rivera
NCI CCR P-ARC
Viviane.rivera@nih.gov

Subject: NCI Bid Board Posting – Biological and Reagents material for the Surgery Branch (SB)

At the National Cancer Institute (NCI), The Surgery Branch (SB) is a combined laboratory and clinical research unit devoted to the development of innovative cancer immunotherapies and their translation to the treatment of patients with cancer. The Surgery Branch was responsible for the development of interleukin-2 (IL-2), the first effective immunotherapy in humans, the development of cell transfer immunotherapies for melanoma and other solid cancers, the first insertion of foreign genes into humans and the first development of effective human cancer immunotherapies based on the genetic engineering of autologous lymphocytes with genes encoding anti-tumor T cell receptors or chimeric antigen receptors.

The primary objective of this purchase from Agilent Technologies preparation supplies and capture kits for sequencing of patient tumor samples. This is being done in concert with clinical trials being held here at the NIH (DHHS).

The National Cancer Institute plans to purchase this Biological and Reagent material from Agilent Technologies, Inc to perform this work. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine if the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on December 3, 2022, ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

The following market research has been conducted and yielded the following outcome: Illumina has a WES kit that is geared towards the HiSeq and MiSeq but unfortunately it is for library prep and capture of small quantities of gDNA. We need to have a kit that starts with a large amount of gDNA which the kit that we are purchasing from Agilent does. The Magnis SureSelect XT-HS2 DNA or RNA Reagent and Human All Exon capture kits and consumables from Agilent Technologies are needed for whole-exome analysis or RNASeq with precise measurement of strand orientation. To ensure continuity of NGS library preparation for exome coverage we must stick with Agilent SureSelect kits as indicated in several recent clinical trial write ups. These reagents will be used to ensure the integrity of the whole-exome library preparation and sequencing on our NextSeq 2000 or NovaSeq 6000 desktop sequencer. These reagents will be used to continue working on sequencing project that is to be used for clinical purposes to aid in gearing treatment plans for patients on Surgery Branch clinical trials.

Attached Documents:

SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request

REQUEST FOR QUOTATION <i>(THIS IS NOT AN ORDER)</i>		THIS RFQ <input type="checkbox"/> IS <input checked="" type="checkbox"/> IS NOT A SMALL BUSINESS SET-ASIDE		PAGE OF 1	PAGES 1
1. REQUEST NUMBER POTS 23-008406	2. DATE ISSUED 11/22/2022	3. REQUISITION/PURCHASE REQUEST NUMBER POTS 23-008406	4. CERT. FOR NAT. DEF. UNDER BDSA REG. 2 AND/OR DMS REG. 1	RATING	
5a. ISSUED BY NIH/NCI-CCR P-ARC			6. DELIVER BY (Date) 12/02/2022		
5b. FOR INFORMATION CALL (NO COLLECT CALLS)			7. DELIVERY <input type="checkbox"/> FOB DESTINATION <input checked="" type="checkbox"/> OTHER (See Schedule)		
NAME Viviane Rivera Chevez, Purchasing Agent		TELEPHONE NUMBER AREA CODE 240 NUMBER 760-7125		9. DESTINATION	
8. TO:			TODD PRICKETT 240-858-3778		
a. NAME		b. COMPANY		b. STREET ADDRESS 10 Center Dr, Bldg/CRC 10 Rm 3W-3864	
c. STREET ADDRESS			c. CITY Bethesda		
d. CITY		e. STATE	f. ZIP CODE	d. STATE MD	e. ZIP CODE 20892
10. PLEASE FURNISH QUOTATIONS TO THE ISSUING OFFICE IN BLOCK 5a ON OR BEFORE CLOSE OF BUSINESS (Date) 12/02/2022		IMPORTANT: This is a request for information and quotations furnished are not offers. If you are unable to quote, please so indicate on this form and return it to the address in Block 5a. This request does not commit the Government to pay any costs incurred in the preparation of the submission of this quotation or to contract for supplies or service. Supplies are of domestic origin unless otherwise indicated by quoter. Any representations and/or certifications attached to this Request for Quotation must be completed by the quoter.			

11. SCHEDULE (Include applicable Federal, State and local taxes)

ITEM NUMBER (a)	SUPPLIES/SERVICES (b)	QUANTITY (c)	UNIT (d)	UNIT PRICE (e)	AMOUNT (f)
1	G9774B Magnis SSEL XT HS2, DNA,HuExon V8,ILM 96	1			\$0.00
2	5500-0148 SureSelect cDNA Module (PrePCR), 16 Rxn Notice of Intent: If submitting a capability statement, please email only 1 copy of the technical capability statement to Viviane Rivera viviane.rivera@nih.gov See attached Statement of Need. This will be awarded as a Firm-Priced Contract.	1			\$0.00
12. DISCOUNT FOR PROMPT PAYMENT		a. 10 CALENDAR DAYS (%)	b. 20 CALENDAR DAYS (%)	c. 30 CALENDAR DAYS (%)	d. CALENDAR DAYS
				0.00	NUMBER PERCENTAGE

NOTE: Additional provisions and representations are are not attached.

13. NAME AND ADDRESS OF QUOTER			14. SIGNATURE OF PERSON AUTHORIZED TO SIGN QUOTATION		15. DATE OF QUOTATION	
a. NAME OF QUOTER			16. SIGNER		b. TELEPHONE	
b. STREET ADDRESS						
c. COUNTY			a. NAME (Type or print)		AREA CODE	
d. CITY		e. STATE	f. ZIP CODE	c. TITLE (Type or print)		NUMBER

STATEMENT OF NEED (SON)

1.0 TITLE

Sequencing of cancer patient samples using the whole-exome sequencing kit to determine the somatic mutation signature.

2.0 BACKGROUND

Agilent Technologies Magnis SureSelect WES XT-HS2 DNA and RNA kits and consumables will be used to generate next-generation sequencing (NGS) ready libraries from immunotherapy cancer patient's tumor samples to determine tumor somatic mutation burden. Our clinical trial(s) here at the NIH/NCI have been utilizing these kits for the past 4-5 years, so maintaining continuity within the protocol is key. Purchase is being made by the National Cancer Institute, procurement being made by Surgery Branch under the direction of Dr. Steven A. Rosenberg, MD/PhD, Branch Chief.

3.0 TYPE OF ORDER

This is a Firm Fixed-Price Purchase Order.

4.0 SPECIAL ORDER REQUIREMENTS

4.1 PRODUCT FEATURES/SALIENT CHARACTERISTICS

The following product features/characteristics are required for this requirement:

- Library prep kit generates either a WES library prep or RNASeq library that is sequencing ready within 8-9hrs
- These new kits, adapted from the original WES XT HS kit now utilizes 10-200ng of starting material compared to 2ug of gDNA for the original kit.
- Library prep kit has the capacity to be sequenced on our in-house NextSeq desktop sequencers and results in an increased total exome coverage from 150X to 250-300X
- This new kit is designed to allow for greater multiplexing of the NGS WES libraries using dual indexes that are paired for the consumer.

4.2 DELIVERY / INSTALLATION

Delivery should be made to the following address:

*NIH/NCI/SB
10 Center Drive
Building 10 CRC, rm 3W3864
Bethesda, MD 20892*

Item shall be delivered within 1-2 days of purchase order award.

4.3 TRAINING

N/A

STATEMENT OF NEED (SON)

5.0 PAYMENT

Payment shall be made *\$20,681.00 in one lump sum*. Payment authorization requires submission and approval of invoices to the COR and NIH OFM, in accordance with the payment provisions listed below:

The following clause is applicable to all Purchase Orders, Task or Delivery Orders, and Blanket Purchase Agreement (BPA) Calls: PROMPT PAYMENT (JUL 2013) FAR 52.232-25. Highlights of this clause and NIH implementation requirements follow:

I INVOICE REQUIREMENTS

- A. An invoice is the Contractor's bill or written request for payment under the contract for supplies delivered or services performed. A proper invoice is an "Original" which must include the items listed in subdivisions 1 through 12, below, in addition to the requirements of FAR 32.9. If the invoice does not comply with these requirements, the Contractor will be notified of the defect within 7 days after the date the designated billing office received the invoice (3 days for meat, meat food products, or fish, and 5 days for perishable agricultural commodities, dairy products, edible fats or oils) with a statement of the reasons why it is not a proper invoice. (See exceptions under II., below.) Untimely notification will be taken into account in the computation of any interest penalty owed the Contractor.
1. Vendor/Contractor: Name, Address, Point of Contact for the invoice (Name, title, telephone number, e-mail and mailing address of point of contact).
 2. Remit-to address (Name and complete mailing address to send payment).
 3. Remittance name must match exactly with name on original order/contract. If the Remittance name differs from the Legal Business Name, then both names must appear on the invoice.
 4. Invoice date.
 5. Unique invoice #s for all invoices per vendor regardless of site.
 6. NBS document number formats must be included for awards created in the NBS: Contract Number; Purchase Order Number; Task or Delivery Order Number and Source Award Number (e.g., Indefinite Delivery Contract number; General Services Administration number); or, BPA Call Number and BPA Parent Award Number.
 7. Data Universal Numbering System (DUNS) or DUNS + 4 as registered in the Central Contractor Registration (CCR).
 8. Federal Taxpayer Identification Number (TIN). In those exceptional cases where a contractor does not have a DUNS number or TIN, a Vendor Identification Number (VIN) must be referenced on the invoice. The VIN is the number that appears after the contractor's name on the face page of the award document.
 9. Identify that payment is to be made using a three-way match.
 10. Description of supplies/services that match the description on the award, by line billed.*

STATEMENT OF NEED (SON)

11. Freight or delivery charge must be billed as shown on the award. If it is included in the item price do not bill it separately. If identified in the award as a separate line item, it must be billed separately.
12. Quantity, Unit of Measure, Unit Price, Extended Price of supplies delivered or services performed, as applicable, and that match the line items specified in the award.*

* NOTE: If your invoice must differ from the line items on the award, please contact the Contracting Officer before submitting the invoice. A modification to the order or contract may be needed before the invoice can be submitted and paid.

- B. Shipping costs will be reimbursed only if authorized by the Contract/Purchase Order. If authorized, shipping costs must be itemized. Where shipping costs exceed \$100, the invoice must be supported by a bill of lading or a paid carrier's receipt.
- C. Mail an original and 1 copy of the itemized invoice to:

National Institutes of Health
Office of Financial Management, Commercial Accounts
2115 East Jefferson Street, Room 4B-432, MSC 8500
Bethesda, MD 20892-8500

For inquiries regarding payment call: (301) 496-6088

In order to facilitate the prompt payment of invoices, it is recommended that the vendor submit a photocopy of the invoice to the "Consignee" designated for the acquisition in blocks 6A – 6E of the face page of the Order/Award document.

II. INVOICE PAYMENT

- A. Except as indicated in paragraph B., below, the due date for making invoice payments by the designated payment office shall be the later of the following two events:
 1. The 30th day after the designated billing office has received a proper invoice.
 2. The 30th day after Government acceptance of supplies delivered or services performed.
- B. The due date for making invoice payments for meat and meat food products, perishable agricultural commodities, dairy products, and edible fats or oils, shall be in accordance with the Prompt Payment Act, as amended.

III. INTEREST PENALTIES

- A. An interest penalty shall be paid automatically, if payment is not made by the due date and the conditions listed below are met, if applicable.
 1. A proper invoice was received by the designated billing office.
 2. A receiving report or other Government documentation authorizing payment was processed and there was no disagreement over quantity, quality, or contractor compliance with a term or condition.

STATEMENT OF NEED (SON)

3. In the case of a final invoice for any balance of funds due the contractor for supplies delivered or services performed, the amount was not subject to further settlement actions between the Government and the Contractor.

B. Determination of interest and penalties due will be made in accordance with the provisions of the Prompt Payment Act, as amended, the Contract Disputes Act, and regulations issued by the Office of Management and Budget.

IV. PROVIDING ACCELERATED PAYMENT TO SMALL BUSINESS SUBCONTRACTORS, FAR 52.232-40 (DEC 2013)

- a) Upon receipt of accelerated payments from the Government, the Contractor shall make accelerated payments to its small business subcontractors under this contract, to the maximum extent practicable and prior to when such payment is otherwise required under the applicable contract or subcontract, after receipt of a proper invoice and all other required documentation from the small business subcontractor.
- b) The acceleration of payments under this clause does not provide any new rights under the prompt Payment Act.

Include the substance of this clause, include this paragraph c, in all subcontracts with small business concerns, including subcontracts with small business concerns for the acquisition of commercial items.